Trials / Completed
CompletedNCT00044720
Study Evaluating Sirolimus in End Stage Renal Disease in High Risk Kidney Transplant Recipients
An Open-label, Concentration Controlled, Randomized, 12 Month Study of Prograf + Rapamune + Cor
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 484 (actual)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 13 Years
- Healthy volunteers
- Not accepted
Summary
The incidence of efficacy failure at 12 months between two regimens.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rapamune |
Timeline
- Primary completion
- 2005-07-01
- Completion
- 2005-07-01
- First posted
- 2002-09-06
- Last updated
- 2009-08-18
Source: ClinicalTrials.gov record NCT00044720. Inclusion in this directory is not an endorsement.